CellField Technologies

CellField Technologies is a biotechnology company that develops microphysiological systems for preclinical drug testing, specializing in joint disease research. Its flagship technology, the Microphysiological Articular Joint In a Chip (MAJIC) system, uses a multi-cell approach to replicate human joint tissue environments in vitro. This modular platform is designed to provide a more accurate, predictive, and cost-effective alternative to traditional animal testing methods in drug development. The company integrates advanced 3D modeling, specialized cell culture techniques, and fluid dynamics to refine its organ-on-a-chip models. By utilizing human cells rather than rodent models, CellField aims to address the high failure rates of drug candidates in clinical trials, particularly for conditions such as osteoarthritis and rheumatoid arthritis. This work is supported by research efforts, including co-culture validation studies published in scientific literature. The company's efforts matter to pharmaceutical partners and researchers by providing more relevant preclinical data, which can streamline drug discovery, reduce costs, and support ethical commitments to decreasing reliance on animal research. Through its development of specialized joint-on-a-chip platforms, CellField focuses on creating faster and more successful pathways for bringing new joint disease therapies to market.